Merck's Isentress Approved for All Adult HIV Patients
This article was originally published in The Pink Sheet Daily
Isentress in combination therapy has less effect on lipid levels than standard of care Sustiva-based therapy in HIV treatment naïve patients, study shows.
You may also be interested in...
In a bid to patch over their respective weaknesses in the HIV marketplace, GlaxoSmithKline and Pfizer announced April 16 they are forming a jointly owned company combining their portfolios of existing and developing drugs
Emerging data on initiating anti-retroviral treatment earlier in HIV patients could broaden the treatment-naïve market.
Drug makers need to continue investing in early-stage research to unveil the next $1 billion-plus drug, panelists at the Argyle conference agree.